Abstract
BackgroundCancerous cells can utilize immune checkpoints to escape T-cell-mediated cytotoxicity. Agents that target PD-1, PD-L1 and CTLA4 are collectively deemed immune checkpoint inhibitors (ICIs), and many have been approved for...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have